Horizon Therapeutics Public Limited Company
Ticker
HZNP
ISIN
IE00BQPVQZ6
Price
-
Change Today
-
Price 1 year ago
-
Market Capitalization
15,952,320,512.00
Price evolution
Yearly Returns
Peers
Peers
Company information
Summary
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Sector
Healthcare
Industry
Drug Manufacturers—General
Country
Ireland
Exchange
NMS
Earnings Per Share
1.81
P/E Ratio
38.856358
Debt/Equity Ratio
55.731
Beta
1.156662
Ebitda
973,361,024.00
Ebitda Margins
0.26
Enterprise to Ebitda
20.67
Enterprise Value
20,115,394,560.00
Target Price
-
Estimated Price
-
Book Value
18.19
Expected Growth
-
Balance sheet
Income statement
Sustainability
Correlation
| Company | Name | Correlation |
|---|---|---|
| 4568.T | DAIICHI SANKYO COMPANY LIMITED | -0.17 |
| KLBF.JK | Kalbe Farma Tbk. | -0.07 |
| 600276.SS | JIANGSU HENGRUI MEDICAL CO LTD | -0.04 |
| 600436.SS | ZHANGZHOU PIENTZEHUANG PHARMACE | 0.06 |
| MYX.AX | M PHARMA FPO | 0.06 |
| 600771.SS | GUANGYUYUAN CHINESE HERBAL MEDI | 0.09 |
| 300006.SZ | CHONGQING LUMMY PH | 0.16 |
| 600713.SS | NANJING PHARMACEUTICAL CO LTD | 0.16 |
| 4503.T | ASTELLAS PHARMA | 0.17 |
| LLY | Eli Lilly and Company | 0.21 |
| NOVN.SW | NOVARTIS N | 0.21 |
| PFE | Pfizer, Inc. | 0.22 |
| 600867.SS | TONGHUA DONGBAO MEDICINES CO LT | 0.22 |
| GILD | Gilead Sciences, Inc. | 0.22 |
| AMGN | Amgen Inc. | 0.23 |
| 4519.T | CHUGAI PHARMACEUTICAL CO | 0.26 |
| BMY | Bristol-Myers Squibb Company | 0.27 |
| GSK.L | GSK PLC | 0.29 |
| ABBV | AbbVie Inc. | 0.30 |
| SNY | Sanofi | 0.30 |
| JNJ | Johnson & Johnson | 0.34 |
| 600572.SS | ZHEJIANG CONBA PHARMACEUTICAL C | 0.36 |
| 1093.HK | CSPC PHARMA | 0.37 |
| GSK | GSK plc | 0.38 |
| MRK | Merck & Company, Inc. | 0.39 |
| ECILC.IS | ECZACIBASI ILAC | 0.48 |
| AZN | Astrazeneca PLC | 0.57 |
| 600613.SS | SHANGHAI SHENQI PHARM INVEST MA | 0.63 |
| 2186.HK | LUYE PHARMA | 0.64 |
Similar companies
| Ticker | Name | City | Country | Currency | Exchange | Beta | EV/EBITDA | Employees | Site |
|---|---|---|---|---|---|---|---|---|---|
| 600276.SS | JIANGSU HENGRUI MEDICAL CO LTD | Lianyungang | China | CNY | SHH | 58.73 | 24491 | https://www.hrs.com.cn | |
| KLBF.JK | Kalbe Farma Tbk. | Jakarta | Indonesia | IDR | JKT | 0.50 | 14.50 | 12392 | https://www.kalbe.co.id |
| 1093.HK | CSPC PHARMA | Shijiazhuang | China | HKD | HKG | 0.67 | 12.86 | 24746 | https://www.cspc.com.hk |
| 300006.SZ | CHONGQING LUMMY PH | Chongqing | China | CNY | SHZ | 0.83 | -32.33 | 935 | https://www.cqlummy.com |
| PFE | Pfizer, Inc. | New York | United States | USD | NYQ | 0.68 | 6.88 | 79000 | https://www.pfizer.com |
| 600572.SS | ZHEJIANG CONBA PHARMACEUTICAL C | Hangzhou | China | CNY | SHH | 0.46 | 10.69 | 8589 | https://www.conbagroup.com |
| 600713.SS | NANJING PHARMACEUTICAL CO LTD | Nanjing | China | CNY | SHH | 0.46 | 9.37 | 5062 | https://www.njyy.com |
| 600867.SS | TONGHUA DONGBAO MEDICINES CO LT | Tonghua | China | CNY | SHH | 0.24 | 12.42 | https://www.thdb.com | |
| ECILC.IS | ECZACIBASI ILAC | Istanbul | Turkey | TRY | IST | 0.20 | 71.70 | 336 | https://www.eczacibasi.com.tr/en/eczacibasi-gruop/companies/other-products-and-services |
| GSK.L | GSK PLC | Brentford | United Kingdom | GBp | LSE | 0.32 | 6.22 | 90096 | https://www.gsk.com |
| MRK | Merck & Company, Inc. | Kenilworth | United States | USD | NYQ | 0.36 | 10.37 | 67000 | https://www.merck.com |
| BMY | Bristol-Myers Squibb Company | New York | United States | USD | NYQ | 0.44 | 8.87 | 32200 | https://www.bms.com |
| 600771.SS | GUANGYUYUAN CHINESE HERBAL MEDI | Xi'an | China | CNY | SHH | 0.55 | -48.11 | 1900 | https://www.guangyuyuan.com |
| GILD | Gilead Sciences, Inc. | Foster City | United States | USD | NMS | 0.39 | 7.19 | 14400 | https://www.gilead.com |
| JNJ | Johnson & Johnson | New Brunswick | United States | USD | NYQ | 0.57 | 14.45 | 141700 | https://www.jnj.com |
| GSK | GSK plc | Brentford | United Kingdom | USD | NYQ | 0.18 | 8.08 | 90096 | https://www.gsk.com |
| AZN | Astrazeneca PLC | Cambridge | United Kingdom | USD | NMS | 0.12 | 18.55 | 83100 | https://www.astrazeneca.com |
| ABBV | AbbVie Inc. | North Chicago | United States | USD | NYQ | 0.75 | 11.46 | 50000 | https://www.abbvie.com |
| 2186.HK | LUYE PHARMA | Yantai | China | HKD | HKG | 0.75 | 14.06 | 4845 | https://www.luye.cn |
| 600613.SS | SHANGHAI SHENQI PHARM INVEST MA | Shanghai | China | CNY | SHH | 0.36 | 22.96 | 1371 | https://www.gzsq.com |
| MYX.AX | M PHARMA FPO | Salisbury South | Australia | AUD | ASX | 1.09 | 27.98 | https://www.maynepharma.com | |
| 4568.T | DAIICHI SANKYO COMPANY LIMITED | Tokyo | Japan | JPY | JPX | 52.12 | 16458 | https://www.daiichisankyo.com | |
| 4503.T | ASTELLAS PHARMA | Tokyo | Japan | JPY | JPX | 0.58 | 12.39 | 14522 | https://www.astellas.com |
| NOVN.SW | NOVARTIS N | Basel | Switzerland | CHF | EBS | 0.50 | 10.30 | 108000 | https://www.novartis.com |
| SNY | Sanofi | Paris | France | USD | NMS | 0.36 | 9.75 | 95442 | https://www.sanofi.com |
| HZNP | Horizon Therapeutics Public Lim | Dublin | Ireland | USD | NMS | 1.16 | 20.67 | 1940 | https://www.horizontherapeutics.com |
| LLY | Eli Lilly and Company | Indianapolis | United States | USD | NYQ | 0.37 | 29.00 | 35000 | https://www.lilly.com |
| AMGN | Amgen Inc. | Thousand Oaks | United States | USD | NMS | 0.58 | 12.61 | 24200 | https://www.amgen.com |
| 4519.T | CHUGAI PHARMACEUTICAL CO | Tokyo | Japan | JPY | JPX | 0.64 | 9.60 | 7664 | https://www.chugai-pharm.co.jp |
| 600436.SS | ZHANGZHOU PIENTZEHUANG PHARMACE | Zhangzhou | China | CNY | SHH | 0.78 | 57.53 | 2591 | https://www.zzpzh.com.cn |
| BAYN.DE | BAYER AG | Leverkusen | Germany | EUR | GER | 1.16 | 13.66 | 101914 | https://www.bayer.com |
| AZN.L | ASTRAZENECA PLC ORD SHS $0.25 | Cambridge | United Kingdom | GBp | LSE | 0.10 | 15.96 | 83100 | https://www.astrazeneca.com |
| 300357.SZ | ZHEJIANG WOLWO BIO | Huzhou | China | CNY | SHZ | 0.40 | 56.57 | 1488 | https://www.wolwobiotech.com |
| SAN.PA | SANOFI | Paris | France | EUR | PAR | 0.36 | 9.86 | 95442 | https://www.sanofi.com |
| NVS | Novartis AG | Basel | Switzerland | USD | NYQ | 0.49 | 10.62 | 108000 | https://www.novartis.com |
| 0P6S.IL | BAYER AG | Leverkusen | Germany | EUR | IOB | 1.15 | 9.51 | 100753 | https://www.bayer.com |
| CIPLA.NS | CIPLA LTD | Mumbai | India | INR | NSI | 17.91 | https://www.cipla.com | ||
| 4528.T | ONO PHARMACEUTICAL CO | Osaka | Japan | JPY | JPX | 0.33 | 13.40 | 3687 | https://www.ono-pharma.com |
| 4536.T | SANTEN PHARMACEUTICAL CO | Osaka | Japan | JPY | JPX | 0.37 | 7.05 | 4315 | https://www.santen.com |
| OGN | Organon & Co. | Jersey City | United States | USD | NYQ | 7.83 | 9300 | https://www.organon.com |
Funds
Mutual Fund Holders
Social
Dividends
Ratings
News
Earnings
SEC Filings
Options
Indicators
Glossary
- Momentum
- A technical indicator that measures the rate of change in price movements over a specific period. It indicates the strength or weakness of a price trend.
Assessment: A positive momentum value generally indicates a good trend, while a negative value suggests a weak or downward trend.
- Inertia
- In trading, inertia refers to the tendency of prices to continue moving in their current direction. It suggests that an asset's price will likely maintain its current trend.
Assessment: A higher inertia value is generally considered good, as it indicates a strong and sustained price trend.
- Relative Strength Index (RSI)
- A momentum oscillator that measures the speed and change of price movements. It helps identify overbought or oversold conditions in an asset.
Assessment: An RSI value above 70 is typically considered overbought and may suggest a potential reversal or correction. Conversely, an RSI value below 30 is often considered oversold, indicating a possible upward price correction.
- Fibonacci's Weighted Moving Average
- A technical indicator that assigns different weights to recent data points, giving more significance to recent prices. It helps smooth out price fluctuations and identify trend reversals.
Assessment: The interpretation of the Fibonacci's Weighted Moving Average value depends on its comparison to other moving averages or trendlines. A value above 50 may indicate an uptrend, while a value below 50 may suggest a downtrend.
- Williams %R
- A momentum indicator that measures overbought or oversold conditions in an asset. It shows the relationship of the current closing price to the high-low range over a specified period.
Assessment: Williams %R values above -20 are typically considered overbought and may indicate a potential price reversal. Values below -80 are often viewed as oversold, suggesting a potential price bounce.
- Relative Volatility Index (RVI)
- A technical indicator that measures the volatility of a security by comparing the magnitude of recent price movements to the magnitude of average price changes. It helps identify periods of high or low volatility.
Assessment: A higher RVI value suggests higher volatility, which can provide trading opportunities but also carries increased risk.
- Commodity Channel Index (CCI)
- A versatile indicator that measures the current price level relative to an average price level over a given period. It helps identify overbought or oversold conditions and potential trend reversals.
Assessment: CCI values above 100 are often considered overbought, indicating a potential price correction or reversal. Values below -100 are typically viewed as oversold, suggesting a potential price rebound.